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Summary 
Objective: Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is a 
common epilepsy syndrome often poorly controlled by antiepileptic drug (AED) 
treatment. Comparative AED effectiveness studies in this condition are lacking. We 
report retention, efficacy and tolerability in a cohort of patients with MTLE-HS. 
Methods: Clinical data were collected from a European database of patients with 
epilepsy. We estimated retention, 12-month seizure freedom and adverse drug 
reaction (ADR) rates for the 10 most commonly used AEDs in patients with MTLE-HS. 
Results: Seven hundred sixty-seven patients with a total of 3249 AED trials were 
included. The highest 12-month retention rates were observed with carbamazepine 
(85.9%), valproate (85%) and clobazam (79%). Twelve-month seizure freedom rates 
varied from 1.2% for gabapentin and vigabatrin to 11% for carbamazepine. Response 
rates were highest for AEDs prescribed as initial treatment and lowest for AEDs used 
in third or higher instance. ADRs were reported in 47.6% of patients, with the highest 
rates observed with oxcarbazepine (35.7%), topiramate (30.9%) and pregabalin 
(27.4%), and the lowest rates with clobazam (6.5%), gabapentin (8.9%) and 
lamotrigine (16.6%). The most commonly reported ADRs were lethargy and 
drowsiness, dizziness, vertigo and ataxia, and blurred vision and diplopia. 
Significance: Our results did not demonstrate any clear advantage of newer versus 
older AEDs. Our results provide useful insights in AED retention, efficacy and ADR 
rates in patients with MTLE-HS. 
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Introduction 
Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is one of the 
most common epilepsy syndromes, accounting for up to 65% of patients with 
temporal lobe epilepsy.1 Antiepileptic drug (AED) resistance is common in patients 
with MTLE-HS and hippocampal sclerosis is identified in about one third of patients 
with drug-resistant epilepsy undergoing surgical resection.2 Several studies have 
demonstrated that patients with MTLE-HS are significantly less likely to respond to 
AEDs compared to patients with other focal epilepsy syndromes3 and surgery is 
considered superior to prolonged medical treatment in patients who do not respond 
to initial treatment.4,5 Conversely, it is clear that a subgroup of patients with MTLE-
HS have seizures that are controlled with AEDs and that the size of this subgroup is 
systematically underestimated in studies of MTLE-HS, which are mostly conducted in 
tertiary epilepsy centers.6 Moreover, a substantial number of patients with MTLE-HS 
do not undergo surgery for a variety of reasons, including the presence of bilateral 
lesions, high probability of postoperative neuropsychological deficits or individual 
choice.7 A wide variety of AEDs with differing mechanisms of action and adverse 
event profiles is now available for the treatment of focal epilepsy. Numerous 
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randomized clinical trials in focal epilepsy have been conducted. These are focused 
on a particular AED, rather than specific syndromic subgroups such as the population 
with MTLE-HS.8 There is therefore a lack of reliable evidence upon which to base 
guidelines for AED treatment for patients with MTLE-HS. As a consequence, the 
medical treatment of these patients largely remains a process of trial and error and 
any evidence of superiority of one AED over another is lacking. A number of 
comparative effectiveness studies in patients with focal epilepsy have been reported, 
but again these have included patients with various types of epilepsy.9,10 To address 
this knowledge gap, we have evaluated effectiveness by comparing 12-month 
retention, efficacy (seizure freedom), and tolerability of commonly-used AEDs in a 
large population of patients with MTLE-HS. 
Methods 
Patients with MTLE-HS were identified from a large clinical database developed by 
the EpiPGX consortium, a European multicentre research project on epilepsy 
pharmacogenetics (www.epipgx.eu). This database contains phenotypic information 
collected from medical records on over 12000 patients with a confirmed diagnosis of 
epilepsy, with detailed information on more than 40000 AED trials. Data collection 
was approved by the Institutional Review Boards of the participating centres and all 
patients provided written informed consent for use of their clinical data.  
We identified 806 patients with a diagnosis of MTLE-HS, recruited from epilepsy 
centres in Belgium, Germany, Ireland, Italy, the Netherlands and the United Kingdom. 
The diagnosis of MTLE-HS was confirmed on MRI and/or pathological examination in 
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all individuals. Thirty-four patients with dual pathology were excluded. All AED trials 
from the time of treatment initiation were considered, with the following exclusions: 
i) trials started less than one year before the last clinic visit or less than one year 
before epilepsy surgery, (ii) trials started after epilepsy surgery, (iii) AEDs with 
average start date before 1985 (phenobarbital, primidone, phenytoin), and (iv) 23 
AEDs used in fewer than 70 patients. However, when considering order of AED use, 
all AEDs and all AED trials were included. The final study population included 767 
patients with 3249 trials on 10 different AEDs (see Figure 1).  
We recorded duration of treatment, maximum dose, and order of prescription for 
each of the 3249 AED trials (see Table 2, Supplementary Figure 2 and Table 2). As 
AED duration data contained some extreme values, we calculated median treatment 
duration, which is more robust to outliers. 
Estimation of 12-month retention rates was done for the 1288 AED trials for which 
information on duration of treatment was available. For cases with ongoing treatment 
we considered the date of the last visit if recorded. Twelve-month retention was 
defined as the proportion of exposed patients remaining on the AED for a period of at 
least 12 months. We also represented retention as a survival analysis, with median 
retention estimate as the outcome variable. 
Efficacy of AED trials was categorized based on the Consensus proposal of the 
International League Against Epilepsy11 as follows: 1) response (freedom from all 
seizures lasting for ≥ 12 months, which according to the treating clinician and/or the 
person undertaking phenotyping can be attributed to the AED, and prior to initiation 
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of another treatment for epilepsy), 2) failure (seizures recurring at >50% of the 
pretreatment seizure frequency after the appropriate AED has been adequately 
used), 3) unclassified (i.e. neither response nor failure) or 4) unknown. Population 
percentage response was calculated as the number of responses divided by the total 
number of known outcomes (response, failure and unclassified). 
Lastly, we calculated overall adverse drug reaction (ADR) incidence per AED and the 
most frequently reported ADRs for each AED. For the purpose of this study, ADRs had 
to be reported by the treating clinician and/or the person undertaking phenotyping 
as attributable to the specific AED. All analyses were performed using R software.12 
To compare the results of median retention, response and ADR rates between AEDs, 
we compared each AED with the other AEDs in a 2x2 comparison with χ2 analyses. 
We calculated p-values by Fisher exact test when χ2 analyses included data with 
expected values less than 5. All reported p-values were corrected for multiple 
comparisons by Bonferroni correction, considering the number of observations as n 
or n(n-1)/2 in case of pairwise comparisons. 
Results 
Demographic and clinical details of the patient cohort are presented in Table 1. 
Treatment details of each AED are presented in Table 2. 
Carbamazepine, used by 615 patients (80.2 %) and valproate, used by 477 patients 
(62.2 %) were the most commonly used AEDs. 
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Drug retention 
Carbamazepine with median survival rate of 3.27 years and valproate with median 
survival rate of 3 years had the highest retention estimates. 
The retention estimate of carbamazepine was statistically higher than those of 
pregabalin, oxcarbazepine, gabapentin, lamotrigine and topiramate (Bonferroni 
corrected p-value < 0.01; see Figure 2). 
The reason for AED discontinuation was recorded in 54.5% of treatments. The main 
reasons were lack of efficacy (26.9%) and ADRs (12.8%). See Supplementary Table 3 
for details. 
Efficacy 
Table 3 shows the treatment outcomes and response (seizure freedom) rates for the 
10 AEDs. Twelve-month seizure freedom rates varied between 1.2% for gabapentin 
and vigabatrin and 11% for carbamazepine, while failure rates varied between 41.9% 
for pregabalin and 71.8% for oxcarbazepine. Pairwise comparison of response rates 
of the 10 AEDs did not show any statistically significant differences. 
Seizure freedom rates per AED were too low to allow any correlations between 
response rate and AED prescription order. Considering all 10 AEDs together, the 
response rates on AEDs used as the first treatment were higher than those on AEDs 
used in third or higher instance (13.3% versus 4.92%, p<0.001). 
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Adverse drug reactions 
ADRs were reported in 365 (47.6 %) patients. The incidence of the 10 most frequent 
ADRs is presented in Table 4. 
ADRs were most commonly reported with oxcarbazepine, topiramate and pregabalin 
(35.7, 30.9 and 27.4% of treated patients, respectively). The most commonly reported 
ADRs were lethargy and drowsiness, dizziness, vertigo and ataxia and blurred vision 
and diplopia (17.9, 13.9 and 9.5% of occurrence in all cases, respectively). 
ADR rate amongst patients on oxcarbazepine (50 out of 140) was significantly higher 
than on carbamazepine, clobazam, gabapentin, levetiracetam, lamotrigine and 
vigabatrin (p < 0.002 for all), as well as on valproate (p < 0.03). Similarly, ADR rate on 
topiramate (94 patients out of 304) was significantly higher than on carbamazepine, 
clobazam, gabapentin, levetiracetam and lamotrigine (p < 0.003 for all), as well as on 
vigabatrin (p < 0.02). ADR rate on pregabalin (20 patients out of 73) was significantly 
higher than on clobazam (p < 0.001) and gabapentin (p = 0.01). 
Discussion 
Although MTLE-HS represents a well-known and common clinical entity, large scale 
epidemiological studies are surprisingly scarce. Here we report retention, seizure 
freedom and ADR rates for the 10 most commonly used AEDs in a large cohort of 
patients with MTLE-HS. The data provide a unique picture of AED prescription 
patterns in MTLE-HS in Western Europe over the last decades. Data were collected 
from multiple sites but stored in a single database, containing detailed data on AED 
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trials, and allowing for uniform data capture and extraction. We applied strict 
inclusion criteria for case identification and qualifying AED trials. AEDs started before 
1985 were excluded as details on these treatments were lacking in a large proportion 
of cases and because these AEDs (phenobarbital, primidone, phenytoin) are currently 
rarely used in most Western countries. 
The highest retention rates were seen with carbamazepine, valproate and 
levetiracetam. Reported AED retention rates vary greatly and no previous study has 
addressed the population with MTLE-HS specifically.9,10,13–16 The relatively high 
retention rates observed with carbamazepine and valproate might be explained in 
part by the fact that these AEDs were started earlier on average compared to other 
AEDs, at a time when relatively fewer AED alternatives were available, which may 
have restricted clinicians’ options for switching AEDs. Conversely, carbamazepine 
and valproate were more often the first AED used, resulting in higher response rates 
and fewer drug interactions and ADRs. Retention rates represent a combined 
reflection of efficacy and tolerability. Our results indeed suggest that AEDs with the 
highest retention rates (carbamazepine, valproate and levetiracetam) tend to have 
the highest efficacy rates, while those with the lowest retention rates (pregabalin, 
oxcarbazepine, topiramate) have the highest ADR rates. 
Twelve-month seizure freedom rates per AED ranged from 1.2 to 11%, providing 
support to the concept of the refractoriness of MTLE-HS. Previous studies reporting 
seizure freedom rates in patients with MTLE-HS mostly considered seizure freedom 
at last follow-up, with widely varying results.17,18 A study of 253 patients with MTLE-
Androsova 12 
 
HS recruited from a tertiary referral centre reported 9% seizure freedom at one year 
follow-up.19 A study on 68 patients with newly diagnosed MTLE-HS reported seizure-
free periods of at least a year in 53%.7 In a study of 110 patients with MTLE-HS, 31% 
remained seizure-free for at least two years.20 A similar though smaller study 
reported 29% of 41 patients with MTLE-HS as being seizure-free or having only focal 
aware seizures.21 These two studies were conducted in non-surgical cases only. In 
contrast, our cases were mostly patients with longstanding disease recruited mainly 
from tertiary referral centres. It has been suggested that seizures tend to become 
more refractory over time.3,22 Our figures may represent an underestimation of true 
response rates though, as seizure-free periods may have been missed, especially 
those occurring early in the disease course. Seizure freedom rates were highest with 
carbamazepine, levetiracetam and oxcarbazepine, although the differences were not 
statistically significant. No previous studies reported comparative response to 
individual AEDs in patients with MTLE-HS specifically. In one report the majority of 
34 seizure-free patients were treated either with carbamazepine monotherapy or a 
combination of carbamazepine and levetiracetam, which were also the AEDs with the 
highest efficacy rates in our study.20 In an attempt to differentiate AED response from 
other causes of seizure freedom, we specifically required seizure freedom to occur 
before initiation of another treatment and to be attributable to the AED in question, 
as judged by the clinician or person undertaking phenotyping. We recognize that this 
method involves a degree of subjective interpretation, the extent of which cannot be 
measured. Despite these strict criteria, confounding from polytherapy cannot be 
excluded. Also, in our study as in others, differentiation between natural seizure 
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fluctuation and true AED response is difficult. Prolonged periods of seizure freedom 
are observed in a substantial proportion of patients with epilepsy followed over long 
time periods,23–25 even in those with chronic, refractory epilepsy.26 In a retrospective 
study, 30% of 122 patients with MTLE-HS had a “relapsing-remitting” seizure 
pattern.27 Our strict criteria may have contributed to the relatively low rates of 
seizure freedom observed in our population. Individual seizure freedom rates per 
AED were too low to look at an influence of order of AED use. Considering all 10 AEDs 
together, we noted higher response rates for AEDs used as initial treatment and 
lowest values for AEDs used in third or higher instance. Our data seem to confirm 
previous reports of decreasing rates of response with subsequent AED trials, a well-
known finding also observed in the general epilepsy population.28,29 
ADRs were reported in about half of patients. Prevalence rates of ADRs are known to 
be dependent on the method of assessment.30 Published rates of ADR prevalence 
based on unstructured interviews or spontaneous reporting in patients with epilepsy 
vary between 10 and 40%.31 The higher rate of ADRs in the present study might be 
explained by the fact that most patients were on polytherapy and therefore exposed 
to a higher AED load, although this relationship has not been identified in other 
studies.32,33 ADR rates per AED varied between 6.5% and 35.7%, with the lowest rates 
reported with clobazam, gabapentin and lamotrigine, and the highest with 
oxcarbazepine, topiramate and pregabalin. Our results are comparable with previous 
studies reporting ADR rates on individual AEDs, although most of these concerned 
patients on monotherapy.9,10,34 The most commonly reported ADRs were lethargy 
and drowsiness, dizziness/vertigo/ataxia and blurred vision/diplopia. We 
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acknowledge that the prevalence figures of specific ADRs are likely subject to some 
degree of reporting bias. 
Our results did not show any clear advantage of newer versus older AEDs. Our study 
was largely based on retrospective data collected from medical records, with inherent 
weaknesses and biases. In particular, considerable proportions of data were missing 
for some of the collected items. While some of these data were genuinely missing, this 
is due in part also to the strict definitions we applied, for instance for classifying AED 
efficacy. Our patients were mostly recruited from tertiary referral centres, likely 
resulting in a bias towards more severely affected patients. Our results thus may not 
be applicable to the overall population with MTLE-HS. Also, our data are 
observational and therefore should not be interpreted as evidence of superiority of 
one AED over the other, an issue which can only be addressed in a randomized clinical 
trial in this specific population. It seems unlikely however that randomized clinical 
trials in specific patient populations will be carried out in the foreseeable future. Our 
study is the first to provide an indication of the effectiveness of medical treatments in 
a sizeable cohort of patients with a well-defined focal epilepsy syndrome and the 
results may inform further prospective studies. It is clear that such studies can only 
be realized through large, multicentric collaborations as the one illustrated here. 
Along the lines of recent reports describing the success of personalized treatments in 
specific epilepsy syndromes, mostly of monogenic origin,35–38 these studies may help 
direct treatment in well-characterized subgroups of patients with specific epilepsy 
syndromes, ultimately leading to more efficacious and less harmful treatments. 
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Key Points 
 Comparative AED effectiveness studies in specific focal epilepsy syndromes 
are lacking 
 We conducted a large retrospective database study on effectiveness of 10 
AEDs in patients with MTLE-HS 
 The highest 12-month retention rates were observed with carbamazepine 
 Twelve-month seizure freedom rates on individual AEDs varied from 1.2% to 
11% 
 ADRs were reported in nearly half of patients, with the highest rates with 
oxcarbazepine and the lowest with clobazam 
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Figure 1. Flow chart for recruiting the patients with mesial temporal lobe epilepsy 
with hippocampal sclerosis.  
Numbers of antiepileptic drug trials for drug retention, efficacy and adverse drug 
reactions include only those with interpretable data. Abbreviations: AED, anti-
epileptic drug. 
Figure 2. Survival estimates for continuing AED treatments.  
The bar plot shows the median survival estimate per AED. Their pairwise 
comparisons are given below as Bonferroni corrected p-values. Abbreviations: CBZ, 
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carbamazepine; CLB, clobazam; GBP, gabapentin; LEV, levetiracetam; LTG, 
lamotrigine; ; OXC, oxcarbazepine; PGB, pregabalin; TPM, topiramate; VGB, 
vigabatrin; VPA, valproate. 
 
 
 
 
 
 
 
 
 
 
Table 1. Demographic and clinical details of the patient cohort. 
 Mean Range 
Age (years)   
   At last visit 45 15 - 77 
   At epilepsy diagnosis 16 1 - 74 
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Epilepsy duration (years) 30 1 - 71 
AED trials per patient 4 1 - 12 
 Total Number Percentage (%) 
Sex   
   Male 331 43.2 
   Female 436 56.8 
Ethnicity   
   European 637 83.1 
   Other 48 6.3 
   Unknown 82 10.7 
Sclerosis side   
   Left 340 44.3 
   Right 274 35.7 
   Bilateral 40 5.2 
   Unknown 113 14.7 
Seizure type   
   Focal aware 393 51.2 
   Focal impaired awareness 713 93 
   Focal to bilateral tonic-clonic 567 73.9 
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Patients undergoing epilepsy 
surgery 
434 56.6 
 
 
 
 
 
 
 
 
 
 
Table 2. Treatment details of 767 patients for each AED. 
      AED order 
AED No of 
trials 
No of 
patient
s 
12-month 
retention 
rate (%) 
Treatment 
duration 
(median 
months +/- 
MAD) 
Maximum 
dose 
(median 
mg/day) 
AED 1 
(%) 
AED 2 
(%) 
AED 3 
(%) 
Androsova 27 
 
CBZ 659 615 85.9 70 +/- 77.4 1200 29.2 22.4 48.4 
VPA 508 477 85.0 55 +/- 63.1 1500 24.0 18.7 57.3 
LTG 467 458 63.8 22 +/- 26 400 9.9 14.5 75.6 
LEV 431 423 71.3 31 +/- 37.2 2875 4.6 8.4 86.9 
TP
M 
308 304 63.8 17 +/- 17.4 300 5.6 8.7 85.7 
CLB 235 230 79.0 37 +/- 36.9 20 7.1 12.0 80.9 
VGB 233 231 69.4 26 +/- 27.7 2500 3.7 13.0 83.3 
GBP 194 192 64.3 14 +/- 15.3 1800 8.1 9.4 82.5 
OXC 141 140 51.4 12 +/- 15 1500 6.9 11.1 82.0 
PGB 73 73 40.0 10 +/- 9.8 300 1.6 6.3 92.1 
Abbreviations: AED, antiepileptic drug; MAD, median absolute deviation; CBZ, 
carbamazepine; CLB, clobazam; GBP, gabapentin; LEV, levetiracetam; LTG, 
lamotrigine; OXC, oxcarbazepine; PGB, pregabalin; TPM, topiramate; VGB, vigabatrin; 
VPA, valproate. AED 1 means that the AED in question was the first AED used etc. 
Table 3. AED outcome summary. 
AED No of trials Response (%) Failure (%) Unclassified Unknown 
CBZ 659 27 (11) 130 (52.8) 89 413 
VPA 508 15 (7.9) 112 (59.3) 62 319 
LTG 467 12 (5.4) 121 (54.5) 89 245 
LEV 431 24 (9.2) 147 (56.5) 89 171 
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TPM 308 7 (4.2) 104 (63) 54 143 
CLB 235 3 (2.9) 57 (54.3) 45 130 
VGB 233 1 (1.2) 57 (66.3) 28 147 
GBP 194 1 (1.2) 50 (59.5) 33 110 
OXC 141 7 (8.2) 61 (71.8) 17 56 
PGB 73 2 (4.7) 18 (41.9) 23 30 
Unclassified: the outcome is known but can be classified neither as a response nor a 
failure; unknown: the outcome is unknown, e.g. because insufficient information is 
available.  
 
 
 
 
 
 
 
Table 4. Overall ADR incidence and top 10 most frequent ADRs per AED. 
AED Patients 
with ADR 
(%) 
Lethargy/
drowsi-
ness (%) 
Dizziness
/Vertigo
/Ataxia 
(%) 
Blurred 
Vision/ 
Diplopia 
(%) 
Behavio-
ral/emo-
tional 
ADRs 
(%) 
Weight 
change 
(%) 
Cuta-
neous 
ADRs 
(%) 
Cognitive 
impair-
ment (%) 
Tremor 
(%) 
Gastro-
intestina
l ADRs 
(%) 
Depression 
(%) 
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OXC 50 (35.7) 9 (6.4) 13 (9.2) 15 (10.6) 4 (2.8) 0 (0) 6 (4.3) 3 (2.1) 2 (1.4) 2 (1.4) 1 (0.7) 
TPM 94 (30.9) 17 (5.5) 10 (3.2) 0 (0) 20 (6.5) 18 
(5.8) 
2 (0.6) 32 (10.4) 0 (0) 7 (2.3) 13 (4.2) 
PGB 20 (27.4) 4 (5.5) 4 (5.5) 0 (0) 1 (1.4) 4 (5.5) 0 (0) 0 (0) 0 (0) 2 (2.7) 1 (1.4) 
VPA 100 (21) 13 (2.6) 3 (0.6) 0 (0) 3 (0.6) 28 
(5.5) 
4 (0.8) 4 (0.8) 35 (6.9) 14 (2.8) 2 (0.4) 
CBZ 115 
(18.7) 
28 (4.2) 39 (5.9) 38 (5.8) 2 (0.3) 2 (0.3) 13 (2) 1 (0.2) 3 (0.5) 3 (0.5) 2 (0.3) 
LEV 74 (17.5) 31 (7.2) 12 (2.8) 0 (0) 29 (6.7) 0 (0) 1 (0.2) 2 (0.5) 3 (0.7) 6 (1.4) 16 (3.7) 
VGB 39 (16.9) 3 (1.3) 0 (0) 5 (2.1) 0 (0) 5 (2.1) 0 (0) 1 (0.4) 1 (0.4) 0 (0) 4 (1.7) 
LTG 76 (16.6) 17 (3.6) 23 (4.9) 14 (3) 2 (0.4) 0 (0) 31 (6.6) 2 (0.4) 0 (0) 5 (1.1) 1 (0.2) 
GBP 17 (8.9) 7 (3.6) 1 (0.5) 0 (0) 1 (0.5) 3 (1.5) 0 (0) 2 (1) 0 (0) 5 (2.6) 2 (1) 
CLB 15 (6.5) 6 (2.6) 0 (0) 0 (0) 3 (1.3) 1 (0.4) 2 (0.9) 1 (0.4) 1 (0.4) 0 (0) 1 (0.4) 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting information:  
Supplementary Table 1. Breakdown of subjects by centres 
Supplementary Figure 1. Distribution of AED start dates 
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Supplementary Figure 2. AED treatment duration 
Supplementary Table 2. Order of AED use 
Supplementary Figure 3. Frequencies of patients' age distribution 
Supplementary Table 3. Reasons for AED discontinuation 
 
